Adeona Pharmaceuticals has begun the Phase II study of its Trimesta drug, used for the treatment of cognitive dysfunction in multiple sclerosis (MS).
Trimesta is an oral estriol designed for treating relapsing-remitting MS and for cognitive dysfunction in MS, both in female patients, and has been approved throughout Europe and Asia to treat post-menopausal symptoms.
The Phase II trial is a randomized double-blind placebo-controlled study expected to enroll 64 relapsing-remitting or secondary-progressive female MS patients....Read More -
http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1878